12:00 AM
 | 
Sep 02, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

TheraBiologics, University of Chicago, City of Hope preclinical data

In a mouse model of GBM, TBX-03 in combination with temozolomide and radiation increased median survival by about 46%. Additionally, TBX-03 delivered prior to temozolomide and...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >